NO20010844L - Regulation of substrate activity - Google Patents

Regulation of substrate activity

Info

Publication number
NO20010844L
NO20010844L NO20010844A NO20010844A NO20010844L NO 20010844 L NO20010844 L NO 20010844L NO 20010844 A NO20010844 A NO 20010844A NO 20010844 A NO20010844 A NO 20010844A NO 20010844 L NO20010844 L NO 20010844L
Authority
NO
Norway
Prior art keywords
regulation
substrate activity
treatment
activity
dpp
Prior art date
Application number
NO20010844A
Other languages
Norwegian (no)
Other versions
NO20010844D0 (en
Inventor
Barbara P Wallner
Original Assignee
Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Point Therapeutics Inc filed Critical Point Therapeutics Inc
Publication of NO20010844D0 publication Critical patent/NO20010844D0/en
Publication of NO20010844L publication Critical patent/NO20010844L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Fremgangsmåte for å regulere substrataktivitet in vivo som er anvendbar for behandling av medisinske lidelser som inflamma- sjon, arteriosklerose og angiogenese. Fremgangsmåten involverer administrering av en effektiv mengde av en DPP-IV inhibitor til en pasient med behov for slik behandling.A method of regulating substrate activity in vivo useful for the treatment of medical disorders such as inflammation, arteriosclerosis and angiogenesis. The method involves administering an effective amount of a DPP-IV inhibitor to a patient in need of such treatment.

NO20010844A 1998-08-21 2001-02-19 Regulation of substrate activity NO20010844L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9737698P 1998-08-21 1998-08-21
PCT/US1999/018315 WO2000010549A1 (en) 1998-08-21 1999-08-13 Regulation of substrate activity

Publications (2)

Publication Number Publication Date
NO20010844D0 NO20010844D0 (en) 2001-02-19
NO20010844L true NO20010844L (en) 2001-04-23

Family

ID=22263045

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010844A NO20010844L (en) 1998-08-21 2001-02-19 Regulation of substrate activity

Country Status (9)

Country Link
EP (1) EP1104293A1 (en)
JP (1) JP2002523365A (en)
KR (1) KR20010079669A (en)
AU (1) AU5480199A (en)
BR (1) BR9913153A (en)
CA (1) CA2339537A1 (en)
IL (1) IL141471A0 (en)
NO (1) NO20010844L (en)
WO (1) WO2000010549A1 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE04029691T1 (en) 1998-02-02 2007-11-08 Trustees Of Tufts College, Medford Use of dipetidylpeptidase inhibitors to regulate glucose metabolism
CA2331122A1 (en) 1998-05-04 1999-11-11 Point Therapeutics, Inc. Hematopoietic stimulation
DE19828113A1 (en) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
EP1806138A1 (en) * 1999-05-25 2007-07-11 Point Therapeutics, Inc. Anti-tumor agents comprising boroproline compounds
EP1187619A1 (en) * 1999-05-25 2002-03-20 Point Therapeutics, Inc. Anti-tumor agents comprising boroproline compounds
DE19940130A1 (en) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim New effectors of Dipeptidyl Peptidase IV for topical use
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2002213925A1 (en) 2000-09-18 2002-03-26 Osteometer Biotech As Use of glp-1 and flp-2 peptides for treatment of bone disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
CN100579582C (en) 2001-01-02 2010-01-13 Imtm股份有限公司 Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the preparation of medicament for treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of aller
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
WO2003072556A1 (en) * 2001-06-27 2003-09-04 Prosidion Ltd. Glutaminyl based dpiv inhibitors
DE10150203A1 (en) 2001-10-12 2003-04-17 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitor in treatment of cancer
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
EP1469873A4 (en) 2001-11-26 2007-10-03 Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
CA2466870A1 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
SI1480961T1 (en) 2002-02-28 2007-06-30 Prosidion Ltd Glutaminyl based dpiv inhibitors
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
KR20100106630A (en) 2003-05-05 2010-10-01 프로비오드룩 아게 Use of effectors of glutaminyl and glutamate cyclases
EP1620091B1 (en) 2003-05-05 2010-03-31 Probiodrug AG Inhibitors of glutaminyl cyclase
CN1292747C (en) * 2003-09-16 2007-01-03 广东省心血管病研究所 Compound formulation for treating hypertension
WO2005039548A2 (en) 2003-10-15 2005-05-06 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
EP2839832A3 (en) * 2003-11-17 2015-06-24 Novartis AG Use of dipeptidyl peptidase IV inhibitors
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
WO2007033350A1 (en) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
EP1924567B1 (en) 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
KR101281962B1 (en) 2006-04-11 2013-07-08 아레나 파마슈티칼스, 인크. Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
BR112012025592A2 (en) 2010-04-06 2019-09-24 Arena Pharm Inc gpr119 receptor modulators and the treatment of disorders related thereto
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN106075450A (en) * 2011-11-22 2016-11-09 塔夫茨大学信托人 Little molecule reinforcing agent for dendritic cell cancer vaccine
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
KR20180006881A (en) 2015-03-09 2018-01-19 인테크린 테라퓨틱스, 아이엔씨. Methods for the treatment of nonalcoholic fatty liver disease and / or fat dystrophy
JP2020515639A (en) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド PPARγ agonists for the treatment of progressive supranuclear palsy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2099158T3 (en) * 1990-04-14 1997-05-16 New England Medical Center Inc TREATMENT OF REJECTION OF TRANSPLANTS OR AUTOIMMUNE DISEASES AND COMPLEX OF THE GENERAL FORMULA X-PRO-Y-BOROPRO ASSOCIATED WITH THE SAME.
CA2121369C (en) * 1991-10-22 2003-04-29 William W. Bachovchin Inhibitors of dipeptidyl-aminopeptidase type iv
AU4794393A (en) * 1992-07-31 1994-03-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Producing increased numbers of hematopoietic cells by administering inhibitors of dipeptidyl peptidase iv
WO1995011689A1 (en) * 1993-10-29 1995-05-04 Trustees Of Tufts College Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
US6100234A (en) * 1997-05-07 2000-08-08 Tufts University Treatment of HIV
US6534626B1 (en) * 1997-12-01 2003-03-18 The United States Of America As Represented By The Department Of Health & Human Services Chemokine variants
DE04029691T1 (en) * 1998-02-02 2007-11-08 Trustees Of Tufts College, Medford Use of dipetidylpeptidase inhibitors to regulate glucose metabolism
AU765370B2 (en) * 1998-06-05 2003-09-18 Point Therapeutics, Inc. Cyclic boroproline compounds

Also Published As

Publication number Publication date
AU5480199A (en) 2000-03-14
JP2002523365A (en) 2002-07-30
EP1104293A1 (en) 2001-06-06
KR20010079669A (en) 2001-08-22
WO2000010549A1 (en) 2000-03-02
IL141471A0 (en) 2002-03-10
CA2339537A1 (en) 2000-03-02
NO20010844D0 (en) 2001-02-19
BR9913153A (en) 2001-05-15

Similar Documents

Publication Publication Date Title
NO20010844L (en) Regulation of substrate activity
NO20014046L (en) Gabapentin derivatives for the prevention and treatment of visceral pain
BR0212252A (en) Methods to Reduce Hypertension and Heart Failure in a Mammal
MXPA02011339A (en) Treatment of acute coronary syndrome with glp 1.
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
DK0690851T3 (en) Guanidine derivatives useful for treatment
NO20052348L (en) Treatment of hemorrhagic shock
DK0867184T3 (en) Use of tiagabine for the treatment of sleep disorders
EP1007556A4 (en) Troponin subunits and fragments useful as angiogenesis inhibitors
FI964332A (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
HU9401258D0 (en) Treatment of acne or of pseudofolliculitis barbae
IL110943A0 (en) Compositions for the treatment of skin disorders
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
GR3031917T3 (en) Treatment of diseases caused by sebaceous gland disorders with acyl CoA cholesterol acyl transferase inhibitors
DE69424777T2 (en) 3,4-DIARYLCHROMANE FOR TREATING DERMATITIS
EE9700231A (en) Aminotetralin derivative for the treatment of cardiovascular diseases
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
NO20010390L (en) Treatment of anxiety disorders
EE9700350A (en) New use of COMT inhibitors and a method for preventing diabetic vascular disorders
EP0904094A4 (en) Treatment of bone disorders with adrenomedullin
ECSP993110A (en) REGULATION OF SUBSTRATE ACTIVITY
NO20091111L (en) Use of R (+) - alpha- (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidine-methanol for the treatment of sleep disorders
AU5625194A (en) Rectal flunisolide compositions for treating inflammatory intestinal disorders
UA28400A (en) Method for treatment of microbial eczema
MD1296G2 (en) The Nicolau method of tretment of the lichen planus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application